Recruiting

Observational Study

Sponsor:

University of Cincinnati

Code:

NCT01467791

Conditions

Sarcoidosis

Pulmonary Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Observation

Study Details

Brief summary:

Registry to follow patients with sarcoidosis associated pulmonary hypertension

Conditions

Sarcoidosis

Pulmonary Hypertension

Study ID

NCT01467791

Start date

Nov, 2011

Status verified date

Dec, 2015

Completion date

Jan, 2018

Anticipated

Primary completion date

Jan, 2017

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients with sarcoidosis as defined by the ATS/WASOG statement
  • Patients with pulmonary hypertension as confirmed by right heart catheterization
  • Patients willing to provide written informed consent

Exclusion Criteria:

  • Unwillingness to provide assurance that they will complete the follow up visits for the study

Study Design

Enrollment

300 participants

Anticipated

Interventions and Outcome Measures

Arms

Patients

All patients with sarcoidosis associated pulmonary hypertension

Interventions

Observation

Observe patients

Primary outcome measure

  • Survival [ Time Frame: 4 years ]

Central Contacts and Locations

Central contacts

Robert P Baughman, MD

513-584-5225bob.baughman@uc.edu

Rebecca Ingledue

513-584-6252

Locations

University of Cincinnati

Recruiting

Cincinnati, Ohio, United States, 45267

Contacts

Rebecca Ingledue

513-584-6252ingledra@ucmail.uc.edu

Principal Investigator:

Robert P Baughman, MD

More Information

Sponsor

University of Cincinnati

Last update posted

Dec 8, 2015

Last verified

Dec, 2015

Keywords

  • ambrisentan
  • Bosentan
  • Iloprost

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Cincinnati on 2015-12-08.